The goal of a new study published in the Biological Trace Element Research was to investigate the effects of chromium intake on glycemic control, markers of cardio-metabolic risk, and oxidative stress in infertile polycystic ovary syndrome (PCOS) women candidate for in-vitro fertilization (IVF). In this randomized double-blinded, placebo-controlled trial, 40 subjects with infertile PCOS candidate for IVF, aged from 18-40 years, were enrolled. Here, an equal number of participants received either 200 μg/day of chromium or placebo for 8 weeks. It was observed that when compared to the placebo, the intake of chromium supplements led to significant reductions in fasting plasma glucose, insulin levels, homeostatic model of assessment for insulin resistance, and a considerable increase in the quantitative insulin sensitivity check index. Additionally, chromium supplementation markedly decreased serum triglycerides, VLDL- and total cholesterol concentrations when compared to the placebo. Furthermore, taking chromium supplements was associated with a notable increase in plasma total antioxidant capacity and significant reduction in malondialdehyde values, in comparison. Hence, the results indicated that chromium administration for 8 weeks to infertile PCOS women candidate for IVF had beneficial impacts on glycemic control, few variables of cardio-metabolic risk, and oxidative stress.